David A Baldini Net Worth

The estimated Net Worth of David A Baldini is at least $7.6 Thousand dollars as of 23 September 2004. David Baldini owns over 5,000 units of AIM ImmunoTech Inc stock worth over $7,597 and over the last 20 years David sold AIM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Baldini AIM stock SEC Form 4 insiders trading

David has made over 1 trades of the AIM ImmunoTech Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently David bought 5,000 units of AIM stock worth $20,200 on 23 September 2004.

The largest trade David's ever made was buying 5,000 units of AIM ImmunoTech Inc stock on 23 September 2004 worth over $20,200. On average, David trades about 1,667 units every 0 days since 2004. As of 23 September 2004 David still owns at least 24,515 units of AIM ImmunoTech Inc stock.

You can see the complete history of David Baldini stock trades at the bottom of the page.

What's David Baldini's mailing address?

David's mailing address filed with the SEC is 595 GLENGARRY COURT, , EARLYSVILLE, VA, 22936.

Insiders trading at AIM ImmunoTech Inc

Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors, and Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.

What does AIM ImmunoTech Inc do?

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as

Complete history of David Baldini stock trades at AIM ImmunoTech Inc

AIM ImmunoTech Inc executives and stock owners

AIM ImmunoTech Inc executives and other stock owners filed with the SEC include:

• William Mitchell,
  Chairman of the Board
• Thomas K. Equels Esq., J.D., M.S.,
  Exec. Vice Chairman, CEO & Pres
• Thomas Equels,
  Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
• Thomas K. Equels,
  Exec. Vice Chairman, CEO & Pres
• Peter W. Rodino III, Esq., J.D.,
  COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.
• Wayne Springate,
  Senior Vice President - Operations
• David Strayer,
  Chief Scientific & Medical Officer
• Ellen M. Lintal,
  CFO & Chief Accounting Officer
• Charles Jones,
  Investor Relations
• Stewart Appelrouth,
  Director
• Peter Rodino,
  Chief Operating Officer, General Counsel, Secretary
• Ellen Lintal,
  Chief Financial Officer
• Jodie Pelz,
  Controller
• Dr. David R. Strayer M.D.,
  Chief Scientific Officer & Medical Director
• Robert Dickey IV, M.B.A.,
  Chief Financial Officer
• Dr. Ralph Christopher Cavalli Ph.D.,
  VP of QC & Manufacturing
• Dr. Ralph Christopher Cavalli,
  VP of QC & Manufacturing
• Julie Mierau,
  Controller
• Dr. Carol A. Smith,
  Chief Manufacturing Officer & Deputy Chief Scientific Officer
• Ann Marie E. Coverly,
  Director of Admin. & HR and Deputy Investor Relations Coordinator
• Dr. David R. Strayer,
  Chief Scientific Officer & Medical Director
• Roy Robinson,
  Director
• Douglas Hillman,
  President, CEO and Director
• Donald Russell,
  Director
• Thomas E Whytas,
  Director
• David M Vosen,
  Director
• Technik Industries, Inc. El...,
  10% owner
• Kevin J Purcell,
  EVP and Chief Financial Office
• Robert J Mcgill,
  Director
• Mark Perkins,
  Executive V.P.
• Thomas Wright Cason,
  Executive Vice President, COO
• Commercial Bank First,
  10% owner
• Carmelo Russo,
  Executive V.P.
• David A Baldini,
  President and CEO
• Gary E Colbert,
  Executive VP and CFO
• J Mervyn Nabors,
  10% owner
• Nancy Bryan,
  Director